Sugi Predict

Sugi Predict / Compounds / SCHEMBL5027205

SCHEMBL5027205

SCHEMBL5027205

Nc1cncc(-c2ncccn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.48
▸ DYRK1B Q9Y463 2/20 0.45
▸ DYRK1A Q13627 2/20 0.44
▸ MEN1 O00255 3/20 0.42
▸ PSIP1 O75475 1/20 0.42
▸ AXL P30530 1/20 0.42
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ DDO Q99489 1/20 0.41
▸ NTRK1 P04629 1/20 0.40
▸ CYP11B2 P19099 2/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CLK2 P49760 1/20 0.37
▸ CLK3 P49761 1/20 0.37
▸ ADRB2 P07550 1/20 0.36
▸ MAP4K4 O95819 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29933932 1.00 CYP2A6 (0.48) CYP2A6DYRK1BDYRK1AMEN1PSIP1
Hydrochloric Acid SCHEMBL23501615 0.98 CYP2A6 (0.47) CYP2A6DYRK1BDYRK1AMEN1PSIP1
Hydrochloric Acid SCHEMBL29933924 0.98 CYP2A6 (0.47) CYP2A6DYRK1BDYRK1AMEN1PSIP1
SCHEMBL17546483 0.77 ADRB2 (0.41) CYP2A6DYRK1AMEN1PSIP1AXL
SCHEMBL14955802 0.77 ADRB2 (0.41) CYP2A6DYRK1AMEN1PSIP1AXL
SCHEMBL15220476 0.76 CYP2A6 (0.56) CYP2A6DYRK1BDYRK1AMEN1PSIP1
SCHEMBL12117526 0.74 CYP2A6 (0.48) CYP2A6DYRK1ACYP11B2CYP11B1
SCHEMBL23501651 0.74 CYP2A6 (0.48) CYP2A6DYRK1BDYRK1AMEN1KDM4E
SCHEMBL5799279 0.74 PTK2 (0.52) CYP2A6MEN1KDM4EALDH1A1KMT2A
SCHEMBL23501621 0.74 CYP2A6 (0.48) CYP2A6MKNK1MKNK2CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor NIPPON SHINYAKU CO., LTD. (JP) 2025-12-30 — — US disclosed
EP-4516777-A2 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR Nippon Shinyaku Co., Ltd. (JP) 2025-03-05 — — EP disclosed
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR NIPPON SHINYAKU CO., LTD. (JP) 2023-03-30 — — US disclosed
CN-115315421-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2022-11-08 — — CN disclosed
EP-4074376-A1 COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION Nippon Shinyaku Co., Ltd. (JP) 2022-10-19 — — EP disclosed
WO-2021117846-A1 COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION 日本新薬株式会社 2021-06-17 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
EP-3176154-B1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARM INC (US) 2019-02-20 — — EP disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
EP-2782579-A1 PYRAZINE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2013078466-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 — — US disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 — — US disclosed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK CYP2A6 2838/4885DYRK1B 2164/4885DYRK1A 1990/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK CYP2A6 4092/4885DYRK1B 121/4885DYRK1A 142/4885
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor PDGFRA, PDGFRB, PDGFA CYP2A6 3817/4885DYRK1B 3778/4885DYRK1A 3583/4885
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR PDGFRB, PDGFRA, PDGFA CYP2A6 3529/4885DYRK1B 1922/4885DYRK1A 2041/4885
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK CYP2A6 4492/4885DYRK1B 485/4885DYRK1A 493/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CYP2A6 4043/4885DYRK1B 118/4885DYRK1A 136/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CYP2A6 4043/4885DYRK1B 118/4885DYRK1A 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.